|
Tumor response to doxorubicin in vitro treatment. |
||||
| Patient |
Cell number in control samples |
Cell number in treated samples |
Cell number variation (%) |
Response |
|
|
||||
| 1 |
2307 |
1543 |
- 33,12 |
R |
| 2 |
335 |
297 |
- 11,34 |
NR |
| 3 |
2611 |
2472 |
- 5,32 |
NR |
| 4 |
2800 |
2575 |
- 8,04 |
NR |
| 5 |
472 |
216 |
- 54,24 |
R |
| 6 |
445 |
278 |
- 37,53 |
R |
| 7 |
354 |
304 |
- 14,12 |
NR |
| 8 |
1339 |
1412 |
+ 5,45 |
NR |
| 9 |
1581 |
1337 |
- 15,43 |
NR |
| 10 |
1405 |
625 |
- 55,52 |
R |
| 11 |
644 |
656 |
+ 1,86 |
NR |
| 12 |
699 |
700 |
+ 0,14 |
NR |
| 13 |
5414 |
5086 |
- 6,06 |
NR |
| 14 |
2816 |
2602 |
- 7,60 |
NR |
| 15 |
1268 |
1095 |
- 13,64 |
NR |
| 16 |
1851 |
1644 |
- 11,18 |
NR |
| 17 |
11189 |
9691 |
- 13,39 |
NR |
| 18 |
4964 |
3713 |
- 25,20 |
R |
| 19 |
1047 |
1031 |
- 1,53 |
NR |
| 20 |
1869 |
1656 |
- 11,40 |
NR |
| 21 |
1629 |
1199 |
- 26,40 |
R |
| 22 |
1675 |
1234 |
- 26,33 |
R |
| 23 |
1879 |
1722 |
- 8,36 |
NR |
| 24 |
2155 |
2103 |
- 2,41 |
NR |
| 25 |
668 |
576 |
- 13,77 |
NR |
| 26 |
4849 |
4262 |
- 12,11 |
NR |
| 27 |
3329 |
3266 |
- 1,89 |
NR |
| 28 |
4376 |
3396 |
- 22,39 |
R |
| 29 |
3559 |
2863 |
- 19,56 |
NR |
| 30 |
2716 |
2932 |
+ 7,95 |
NR |
| 31 |
4605 |
3569 |
- 22,50 |
R |
| 32 |
5025 |
4242 |
- 15,58 |
NR |
| 33 |
4239 |
4147 |
- 2,17 |
NR |
| 34 |
4334 |
4146 |
- 4,34 |
NR |
| 35 |
3691 |
4131 |
+ 11,92 |
NR |
| 36 |
5841 |
4659 |
- 20,24 |
NR |
| 37 |
2201 |
2256 |
+ 2,50 |
NR |
| 38 |
5578 |
4533 |
- 18,73 |
NR |
|
Cell number was counted in control (untreated) and doxorubicin treated samples. The signal (-) stands for the percentage cell reduction and (+) for the percentage cell increase, in treated as compared to control samples. R: responsive (reduction in cell number ≥ 21.7%); NR: non-responsive (reduction < 21.7%). | ||||
Sobral et al. Acta Veterinaria Scandinavica 2008 50:27 doi:10.1186/1751-0147-50-27 |
||||